US 11,679,116 B2
Topical compositions and methods for treating psoriasis
Gordon J. Dow, Greenbrae, CA (US); Radhakrishnan Pillai, Santa Rosa, CA (US); and Varsha D. Bhatt, San Francisco, CA (US)
Assigned to Bausch Health Ireland Limited, Dublin (IE)
Filed by Bausch Health US, LLC, Bridgewater, NJ (US)
Filed on Jul. 2, 2021, as Appl. No. 17/366,871.
Application 17/366,871 is a continuation of application No. 17/154,591, filed on Jan. 21, 2021.
Application 17/154,591 is a continuation of application No. 16/377,540, filed on Apr. 8, 2019, abandoned.
Application 16/377,540 is a continuation of application No. 15/173,961, filed on Jun. 6, 2016, granted, now 10,251,895, issued on Apr. 9, 2019.
Claims priority of provisional application 62/181,481, filed on Jun. 18, 2015.
Prior Publication US 2021/0330681 A1, Oct. 28, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/573 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61K 9/06 (2006.01); A61K 31/192 (2006.01); A61K 47/26 (2006.01); A61K 9/12 (2006.01); A61K 47/14 (2017.01); A61K 47/44 (2017.01); A61K 9/107 (2006.01); A61K 31/4436 (2006.01)
CPC A61K 31/573 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/107 (2013.01); A61K 9/12 (2013.01); A61K 31/192 (2013.01); A61K 31/4436 (2013.01); A61K 45/06 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01)] 2 Claims
 
1. A pharmaceutical composition consisting essentially of:
tazarotene, 0.045% w/w,
diethyl sebacate, 2.97% w/w,
light mineral oil, 8.03% w/w,
sorbitan monooleate, 0.1% w/w,
sorbitol solution (70%), 10.7% w/w,
methyl paraben, 0.17% w/w,
propyl paraben, 0.03% w/w,
edetate disodium dihydrate, 0.05% w/w,
carbomer copolymer type B, 0.4% w/w,
carbomer homopolymer type A, 0.6% w/w,
sodium hydroxide, q.s. to pH of 5.5±0.5, and
purified water, q.s. to 100% w/w;
wherein the composition is a lotion.